243 related articles for article (PubMed ID: 10417495)
41. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
Gasic S; Korn A; Eichler HG; Oberhummer I; Zapotoczky HG
Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
[TBL] [Abstract][Full Text] [Related]
42. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.
Lee Y; Conroy JA; Stepanavage ME; Mendel CM; Somers G; McLoughlin DA; Olah TV; De Smet M; Keymeulen B; Rogers JD
Br J Clin Pharmacol; 1999 Apr; 47(4):373-8. PubMed ID: 10233200
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.
Longmore J; Razzaque Z; Shaw D; Davenport AP; Maguire J; Pickard JD; Schofield WN; Hill RG
Br J Clin Pharmacol; 1998 Dec; 46(6):577-82. PubMed ID: 9862247
[TBL] [Abstract][Full Text] [Related]
45. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
Bergström M; Westerberg G; Németh G; Traut M; Gross G; Greger G; Müller-Peltzer H; Safer A; Eckernäs SA; Grahnér A; Långström B
Eur J Clin Pharmacol; 1997; 52(2):121-8. PubMed ID: 9174681
[TBL] [Abstract][Full Text] [Related]
46. Interaction between ketoconazole and almotriptan in healthy volunteers.
Fleishaker JC; Herman BD; Carel BJ; Azie NE
J Clin Pharmacol; 2003 Apr; 43(4):423-7. PubMed ID: 12723463
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Smith DA; Cleary EW; Watkins S; Huffman CS; Dilzer SC; Lasseter KC
J Clin Pharmacol; 1998 Aug; 38(8):685-93. PubMed ID: 9725543
[TBL] [Abstract][Full Text] [Related]
48. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.
Tfelt-Hansen P; Ryan RE
Neurology; 2000; 55(9 Suppl 2):S19-24. PubMed ID: 11089515
[TBL] [Abstract][Full Text] [Related]
49. Rizatriptan: an update of its use in the management of migraine.
Wellington K; Plosker GL
Drugs; 2002; 62(10):1539-74. PubMed ID: 12093318
[TBL] [Abstract][Full Text] [Related]
50. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
Dingemanse J; Korn A; Pfefen JP; Güntert TW
Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
[TBL] [Abstract][Full Text] [Related]
51. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
52. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
Seaber EJ; Peck RW; Smith DA; Allanson J; Hefting NR; van Lier JJ; Sollie FA; Wemer J; Jonkman JH
Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
[TBL] [Abstract][Full Text] [Related]
53. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
Holford NH; Guentert TW; Dingemanse J; Banken L
Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
[TBL] [Abstract][Full Text] [Related]
54. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
55. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
[TBL] [Abstract][Full Text] [Related]
56. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.
Pascual J; Vega P; Diener HC; Allen C; Vrijens F; Patel K
Cephalalgia; 2000 Jun; 20(5):455-61. PubMed ID: 11037741
[TBL] [Abstract][Full Text] [Related]
57. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
Dixon R; Engleman K; Kemp J; Ruckle JL
J Child Adolesc Psychopharmacol; 1999; 9(1):35-42. PubMed ID: 10357516
[TBL] [Abstract][Full Text] [Related]
58. Clinical pharmacokinetics of intranasal sumatriptan.
Fuseau E; Petricoul O; Moore KH; Barrow A; Ibbotson T
Clin Pharmacokinet; 2002; 41(11):801-11. PubMed ID: 12190330
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Fraser IP; Han L; Han TH; Li CC; Hreniuk D; Stoch SA; Wagner JA; Linder S; Winner P
Headache; 2012 Apr; 52(4):625-35. PubMed ID: 22289113
[TBL] [Abstract][Full Text] [Related]
60. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
Stepień A; Chalimoniuk M; Strosznajder J
Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
